Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Prospective Natural History Study of Patients with Intractable Venous Malformation and Klippel-Trenaunay Syndrome to Guide Designing a Proof-of-Concept Clinical Trial for Novel Therapeutic Intervention.
Fujino A, Kuniyeda K, Nozaki T, Ozeki M, Ohyama T, Sato I, Kamibeppu K, Tanaka A, Uemura N, Kanmuri K, Nakamura K, Kobayashi F, Suenobu S, Nomura T, Hayashi A, Nagao M, Kato A, Aramaki-Hattori N, Imagawa K, Ishikawa K, Ochi J, Horiuchi S, Nagabukuro H. Fujino A, et al. Among authors: nagabukuro h. Lymphat Res Biol. 2024 Feb;22(1):27-36. doi: 10.1089/lrb.2023.0023. Epub 2023 Dec 19. Lymphat Res Biol. 2024. PMID: 38112724
Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury.
Ohata K, Sugaya T, Nguyen HN, Arai K, Hatanaka Y, Uno K, Tohma M, Uechi T, Sekiguchi K, Oikawa T, Nagabukuro H, Kuniyeda K, Kamijo-Ikemori A, Suzuki-Kemuriyama N, Nakae D, Noiri E, Miyajima K. Ohata K, et al. Among authors: nagabukuro h. Nephrology (Carlton). 2024 Mar;29(3):117-125. doi: 10.1111/nep.14254. Epub 2023 Nov 11. Nephrology (Carlton). 2024. PMID: 37950597
Urinary liver-type fatty acid binding protein is increased in the early stages of the disease with a risk of acute kidney injury induced by histone.
Ohata K, Sugaya T, Nguyen HN, Hatanaka Y, Uno K, Tohma M, Oikawa T, Nagabukuro H, Kuniyeda K, Kamijo-Ikemori A, Suzuki-Kemuriyama N, Nakae D, Noiri E, Miyajima K. Ohata K, et al. Among authors: nagabukuro h. Nephrology (Carlton). 2023 Jun;28(6):345-355. doi: 10.1111/nep.14162. Epub 2023 Apr 19. Nephrology (Carlton). 2023. PMID: 37076661
Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study.
Ogawa Y, Kobayashi T, Honda Y, Kessoku T, Tomeno W, Imajo K, Nakahara T, Oeda S, Nagaoki Y, Amano Y, Ando T, Hirayama M, Isono O, Kamiguchi H, Nagabukuro H, Ogawa S, Satomi Y, Saigusa Y, Takahashi H, Hyogo H, Yoneda M, Saito S, Yamanaka T, Aishima S, Eguchi Y, Kage M, Chayama K, Nakajima A. Ogawa Y, et al. Among authors: nagabukuro h. Hepatol Res. 2020 Aug;50(8):955-965. doi: 10.1111/hepr.13528. Epub 2020 Jul 15. Hepatol Res. 2020. PMID: 32455496
Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model.
van Koppen A, Verschuren L, van den Hoek AM, Verheij J, Morrison MC, Li K, Nagabukuro H, Costessi A, Caspers MPM, van den Broek TJ, Sagartz J, Kluft C, Beysen C, Emson C, van Gool AJ, Goldschmeding R, Stoop R, Bobeldijk-Pastorova I, Turner SM, Hanauer G, Hanemaaijer R. van Koppen A, et al. Among authors: nagabukuro h. Cell Mol Gastroenterol Hepatol. 2017 Oct 14;5(1):83-98.e10. doi: 10.1016/j.jcmgh.2017.10.001. eCollection 2018. Cell Mol Gastroenterol Hepatol. 2017. PMID: 29276754 Free PMC article.
Investigation of piperazine benzamides as human β3 adrenergic receptor agonists for the treatment of overactive bladder.
Harper BH, Wang L, Zhu C, Kar NF, Li B, Moyes CR, Goble SD, Costa M, Dingley K, Di Salvo J, Ha SN, Hurley A, Li X, Miller RR, Nagabukuro H, Salituro GM, Smith S, Struthers M, Hale JJ, Edmondson SD, Berger R. Harper BH, et al. Among authors: nagabukuro h. Bioorg Med Chem Lett. 2017 Feb 15;27(4):1094-1098. doi: 10.1016/j.bmcl.2016.12.033. Epub 2016 Dec 11. Bioorg Med Chem Lett. 2017. PMID: 28089699
Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
Di Salvo J, Nagabukuro H, Wickham LA, Abbadie C, DeMartino JA, Fitzmaurice A, Gichuru L, Kulick A, Donnelly MJ, Jochnowitz N, Hurley AL, Pereira A, Sanfiz A, Veronin G, Villa K, Woods J, Zamlynny B, Zycband E, Salituro GM, Frenkl T, Weber AE, Edmondson SD, Struthers M. Di Salvo J, et al. Among authors: nagabukuro h. J Pharmacol Exp Ther. 2017 Feb;360(2):346-355. doi: 10.1124/jpet.116.237313. Epub 2016 Dec 13. J Pharmacol Exp Ther. 2017. PMID: 27965369
29 results